Monday, November 21, 2016 8:42:20 AM
LAS VEGAS, NV--(Marketwired - Nov 21, 2016) - Cell MedX Corp. (OTCQB: CMXC), Cell MedX Corp. ("Cell MedX" or the "Company"), a development stage bio-tech company focused on the commercialization and development of microcurrent therapeutic devices that promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes, Parkinson's disease, high blood pressure, is pleased to announce that it has appointed Gregory Pek to the Company's advisory board and as a distributor for Hong Kong and the Philippines.
Gregory Pek is a Canadian who has lived in Asia for some 22 years. Mr. Pek's career began in accounting, which led to him becoming an entrepreneur more than 30 years ago. Mr. Pek has been the founder and CEO of various public companies either listed on the U.S. or Canadian markets as well as a Deputy Managing Director of two companies listed in Hong Kong. Along with his extensive experience with early stage development companies, Mr. Pek, has a wide range of experience in distribution, logistics and financial services.
Mr. Pek, under the supervision of a physician, commenced his own observational trials of the eBalance device in Manila, Philippines. Due to the positive response and testimonials of over 25 subjects, Mr. Pek has been devoting the majority of his time to this project.
Mr. Pek will assist the Company in a wide range of functions including, but not limited to; input into the structure of the observational clinical studies and developing marketing strategies in Asia, overall business strategy, and financing.
Mr. Pek commented that, "It is incredibly exciting to be a part of Cell MedX's project, and witness its technology along with hearing the beneficial results attested to by those involved in the observational studies."
Mr. McEnulty, the Company's CEO, stated, "We are excited to welcome Greg Pek to our advisory board. He is a proven entrepreneur with a detailed understanding of business in Asia. Mr. Pek has, very quickly, established himself as a major source of invaluable information for our current project and further development of our eBalance technology."
About Cell MedX Corp.
Cell MedX Corp. is an early development stage bio-tech company focused on the discovery, development and commercialization of therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes, Parkinson's disease, high blood pressure. For more information about the Company and its technology please visit our website at: www.cellmedx.com, for the Company's weekly newsletter, please go to www.cellmedx.com/media/newsletters/
Recent CMXC News
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 03/06/2024 09:49:24 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 02/22/2024 09:38:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/22/2024 05:48:50 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/16/2024 10:01:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 11:08:43 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 08:29:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 08:36:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/27/2023 08:27:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 05:02:47 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/16/2023 09:20:06 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 09/07/2023 09:00:48 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/01/2023 09:18:25 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 08/29/2023 09:20:38 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 06/29/2023 09:10:35 PM
FEATURED Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market • Mar 18, 2024 8:51 AM
FEATURED Prospera Energy Inc. Announces a 508% increase in the 2023 Proven Developed Producing (PDP) Reserve Valuation • Mar 18, 2024 8:09 AM
Greenlite Ventures Enters into Strategic Alliance with Woodway USA • GRNL • Mar 15, 2024 4:00 PM
HealthLynked Welcomes David Rosal as New Chief Financial Officer • HLYK • Mar 13, 2024 8:00 AM
ECGI Holdings, Inc. Announces Continued Efforts in Financial Optimization • ECGI • Mar 13, 2024 8:00 AM
PSYC Begins Business Overhaul Process with Consolidation of 10 Previously Issued Convertible Debentures • PSYC • Mar 13, 2024 7:13 AM